Literature DB >> 22185048

Effect of antihistamine up-dosing in chronic urticaria.

M Ferrer1, J Sastre, I Jáuregui, I Dávila, J Montoro, A del Cuvillo, J Mullol, J Bartra, A Valero.   

Abstract

Chronic urticaria has an important impact upon patient quality of life, and no treatment has yet been developed capable of effectively controlling the disease. The most recent guidelines recommend the use of non-sedating antihistamines at high doses as second-step therapy before resorting to other treatments. The present review examines the studies published to date on the use of H1 antihistamines at doses higher than those indicated as therapeutic doses in chronic urticaria. Most of the studies report no significant differences among the studied doses-only a tendency towards increased response on elevating the dose. There are no clinically well designed, randomized double-blind trials comparing efficacy between therapeutic doses and doses higher than those indicated in the corresponding Summary of Product Characteristics. Likewise, there are insufficient data to conduct a meta-analysis and thus classify the degree of evidence of the few available studies, which moreover present contradictory results. At present, the prescription of high-dose H1 antihistamines is based only on experts opinion. However, considering the high safety profile of these drugs, it would be a good option to evaluate their efficacy at high doses, before moving on to other therapeutic steps.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22185048

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  4 in total

Review 1.  Management of urticaria: not too complicated, not too simple.

Authors:  M Ferrer; J Bartra; A Giménez-Arnau; I Jauregui; M Labrador-Horrillo; J Ortiz de Frutos; J F Silvestre; J Sastre; M Velasco; A Valero
Journal:  Clin Exp Allergy       Date:  2015-04       Impact factor: 5.018

2.  Cupping for patients with chronic urticaria: A systematic review protocol.

Authors:  Xianjun Xiao; Yunzhou Shi; Leixiao Zhang; Wei Cao; Ying Liu; Siyuan Zhou; Mingling Chen; Qianhua Zheng; Ying Li
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

3.  Critical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticaria.

Authors:  Belen Sadaba; Jose Ramon Azanza; Almundena Gomez-Guiu; Raquel Rodil
Journal:  Ther Clin Risk Manag       Date:  2013-05-03       Impact factor: 2.423

Review 4.  Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine.

Authors:  Xue Yan Wang; Margaret Lim-Jurado; Narayanan Prepageran; Pongsakorn Tantilipikorn; De Yun Wang
Journal:  Ther Clin Risk Manag       Date:  2016-04-13       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.